Evidence map›Paper›PMID 42910376›Full record

ArticleOpen life sciences2026

Taxifolin targets HMGCR, LDLR and APOB to ameliorate hyperlipidemia: insights from systems pharmacology and nanoemulsion-based delivery.

Abdullah R Alanzi, Iman Fatima, Muhammad Umer Ashraf, Muhammad Nasir Hayat Malik, Rashed N Herqash, Mostafa E Abugrain, Muhammad Atif, Munawar Abbas, Gideon F B Solre

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abdullah R AlanziDepartment of Pharmacognosy, College of Pharmacy, King Saud University, 11451 Riyadh, Saudi Arabia.ORCID https://orcid.org/0009-0000-2565-6573
Iman FatimaFaculty of Pharmacy, The University of Lahore, Lahore, Pakistan.
Muhammad Umer AshrafFaculty of Pharmacy, The University of Lahore, Lahore, Pakistan.
Muhammad Nasir Hayat MalikFaculty of Pharmacy, The University of Lahore, Lahore, Pakistan.ORCID https://orcid.org/0000-0002-2657-9810
Rashed N HerqashCenter for Research on Medicinal, Aromatic, and Poisonous Plants, DSR, King Saud University, P.O. Box 2457, Riyadh, Saudi Arabia.
Mostafa E AbugrainDepartment of Pharmacognosy, Faculty of Pharmacy, University of Tripoli, Tripoli, Libya.
Muhammad AtifFaculty of Pharmacy, The University of Lahore, Lahore, Pakistan.
Munawar AbbasCollege of Food Science and Technology, Henan University of Technology, Zhengzhou, Henan, 450001, China.
Gideon F B SolreDepartment of Chemistry, Thomas J. R. Faulkner College of Science and Technology, University of Liberia, Monrovia, Montserrado County, Liberia.ORCID https://orcid.org/0000-0002-2861-0674

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperlipidemia is a major risk factor for cardiovascular disease, highlighting the need for safer and effective therapeutic options. This study evaluated the anti-hyperlipidemic potential of taxifolin (TXF) and its nanoemulsion formulation (TXF-NE) using integrated computational and experimental approaches. Network pharmacology identified 177 common targets between TXF and hyperlipidemia, with enrichment analyses linking these targets to lipid metabolism, cholesterol regulation, and inflammatory pathways. Protein-protein interaction analysis revealed key lipid-regulating genes, including HMGCR as a major hub target. Molecular docking predicted favorable interactions of TXF with several lipid metabolism related proteins, including HMGCR, LDLR, APOB, APOA1, and ACSM2A. The predicted interactions provide structural hypotheses regarding potential TXF protein associations.

Indexed as

APOBHMGCRhyperlipidemiaLDLRtaxifolinTXF-NE

Identifiers

PMID42910376
PMCPMC13686381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.